AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm
August 31, 2020 13:02 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
December 06, 2018 07:30 ET
|
Biogen Inc.; Ionis Pharmaceuticals, Inc.
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067Biogen plans to advance BIIB067 to a pivotal clinical studyBiogen paid Ionis Pharmaceuticals a $35 million...
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
October 29, 2018 07:33 ET
|
ProQR Therapeutics N.V.
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in...